To our knowledge, we are the first to report the clinical significance of YAP1 activation in HNSCC and demonstrate that the YAP1 signature can be used as a prognostic biomarker for HNSCC. The gene discussed is YAP1; the disease is head and neck squamous cell carcinoma.